Featured News
View ASX Announcements here.
DEP® irinotecan combination data to be presented at international oncology conference (ASX Announcement)
Sep 27th, 2023
Starpharma today announces the presentation of data that demonstrate the benefits of combining DEP® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.
Read More
VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment (ASX Announcement)
Sep 25th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed recruitment for the post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE™, in patients with COVID-19 in the UK. Recruitment proceeded rapidly and the study successfully enrolled ~200 patients with laboratory-confirmed COVID-19.
Read More
Positive DEP® irinotecan clinical results to be presented at international oncology conference (ASX Announcement)
Sep 13th, 2023
Starpharma today announces positive interim results from its Phase 1/2 clinical trial of DEP® irinotecan will be presented at the upcoming American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Boston, US, from 11 to 15 October 2023.
Read More
Change of Company Secretary (ASX Announcement)
Aug 28th, 2023
Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.
Read More
